SPRO – spero therapeutics, inc. (US:NASDAQ)

News

Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "hold" rating re-affirmed by analysts at TD Cowen.
Spero Therapeutics, Inc. (NASDAQ: SPRO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update [Yahoo! Finance]
Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com